文献速递肾癌与肾肿瘤

转移性肾细胞癌减瘤性肾切除术围手术期并发症的发生率与预测因素:REMARCC登记分析

Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2020-05-12

基于REMARCC登记中14家机构736例接受减瘤性肾切除术的转移性肾细胞癌患者,回顾性分析围手术期并发症及预测因素。术中并发症10.9%,术后任何级别并发症29.5%,高级别并发症6.1%(其中1.4%死亡),30天再入院11.5%。血栓切除和邻近器官切除预测术中并发症,估计出血量预测任何级别并发症,中心手术量和估计出血量预测高级别并发症。

要点

  • 减瘤性肾切除术并发症不可忽视,高级别并发症6.1%,死亡率1.4%。
  • 估计出血量是术后任何级别和高级别并发症的显著预测因素。
  • 中心手术量高与较低的高级别并发症相关,支持复杂手术集中化。

核心结论

  • 减瘤性肾切除术相关并发症不可忽视,高级别术后并发症的预测因素主要是复杂手术的指标。
  • 估计出血量是术后并发症的强预测因素,中心手术量与较低的高级别并发症相关,支持复杂手术集中化。

研究设计与样本

  • 回顾性登记研究,纳入14家机构736例接受减瘤性肾切除术的转移性肾细胞癌患者,数据录入REMARCC登记。

主要发现

  • 多因素分析中,血栓切除(OR 1.38,95%CI 1.08-1.75,p=0.009)和邻近器官切除(OR 2.7,95%CI 1.38-5.30)是术中并发症的显著预测因素。
  • 估计出血量(OR 1.49,95%CI 1.08-2.05,p=0.01)是任何级别术后并发症的显著预测因素。
  • 中心手术量(OR 0.13,95%CI 0.03-0.59,p=0.009)和估计出血量(OR 2.93,95%CI 1.20-7.15,p=0.02)是高级别术后并发症的显著预测因素,30天再入院未发现显著预测因素。

临床怎么用

  • 术前评估应关注估计出血量、是否需要血栓切除或邻近器官切除以及治疗中心的手术量,以识别高风险患者。
  • 对于复杂减瘤性肾切除术,建议在手术量大的中心进行,以降低高级别并发症风险。
  • 在考虑减瘤性肾切除术时,需权衡风险与获益。

局限性

  • 回顾性研究设计。
  • 结果在仅针对靶向治疗时代患者的亚组分析中得到确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytoreductive nephrectomy (CN) plays an important role in the treatment of a subgroup of metastatic renal cell carcinoma (mRCC) patients. OBJECTIVE: We aimed to evaluate morbidity associated with this procedure and identify potential predictors thereof to aid patient selection for this procedure and potentially improve patient outcomes. DESIGN, SETTING, AND PARTICIPANTS: Data from 736 mRCC patients undergoing CN at 14 institutions were retrospectively recorded in the Registry for Metastatic RCC (REMARCC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression analysis was used to identify predictors for intraoperative, any-grade (AGCs), low-grade, and high-grade (HGCs) postoperative complications (according to the Clavien-Dindo classification) as well as 30-d readmission rates. RESULTS AND LIMITATIONS: Intraoperative complications were observed in 69 patients (10.9%). Thrombectomy (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.08-1.75, p = 0.009) and adjacent organ removal (OR 2.7, 95% CI 1.38-5.30) were significant predictors of intraoperative complications at multivariable analysis. Two hundred seventeen patients (29.5%) encountered AGCs, while 45 (6.1%) encountered an HGC, of whom 10 (1.4%) died. Twenty-four (3.3%) patients had multiple postoperative complications. Estimated blood loss (EBL; OR 1.49, 95% CI 1.08-2.05, p = 0.01) was a significant predictor of AGCs at multivariable analysis. CN case load (OR 0.13, 95% CI 0.03-0.59, p = 0.009) and EBL (OR 2.93, 95% CI 1.20-7.15, p = 0.02) were significant predictors solely for HGCs at multivariable analysis. Forty-one patients (11.5%) were readmitted within 30 d of surgery. No significant predictors were identified. Results were confirmed in a subanalysis focusing solely on patients treated in the contemporary targeted therapy era. CONCLUSIONS: Morbidity associated with CN is not negligible. Predictors of high-grade postoperative morbidity are predominantly indicators of complex surgery. EBL is a strong predictor of postoperative complications. CN case load correlates with lower high-grade morbidity and highlights the benefit of centralization of complex surgery. However, risks and benefits should be balanced when considering CN in mRCC patients. PATIENT SUMMARY: We studied patients with metastatic renal cancer to evaluate the outcomes associated with the surgical removal of the primary kidney tumor. We found that this procedure is often complex and adverse events are not uncommon. High intraoperative blood loss and a small number of cases performed at the treating center are associated with a higher rate of postoperative complications.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Roussel E, Campi R, Larcher A, et al. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2020. PMID: 32414697. doi:10.1016/j.euo.2020.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。